Monoclonal antibodies are single cell clones of antibodies, a biochemical tool that allows scientists to create antibodies that combine the specificity of specific substances. There are many reasons for the medical community to support the use of monoclonal antibodies in cancer treatment. There are a few clinical trials.

Market Analysis and Insights: Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market

The global Cancer Monoclonal Antibody Partnering Terms and Agreements market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Cancer Monoclonal Antibody Partnering Terms and Agreements is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Cancer Monoclonal Antibody Partnering Terms and Agreements is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The Europe market for Cancer Monoclonal Antibody Partnering Terms and Agreements is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The global key companies of Cancer Monoclonal Antibody Partnering Terms and Agreements include 3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension and Ascentage Pharma, etc. In 2023, the global top five players had a share approximately % in terms of revenue.

Cancer Monoclonal Antibody Partnering Terms and Agreements is widely used in various fields, such as Pharmaceutical Industry, Biotechnology, Medical Care and Education and Research, etc. Pharmaceutical Industry provides greatest supports to the Cancer Monoclonal Antibody Partnering Terms and Agreements industry development. In 2023, global % revenue of Cancer Monoclonal Antibody Partnering Terms and Agreements went into Pharmaceutical Industry filed and the proportion will reach to % in 2030.

Report Covers:

This report presents an overview of global market for Cancer Monoclonal Antibody Partnering Terms and Agreements market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Cancer Monoclonal Antibody Partnering Terms and Agreements, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Cancer Monoclonal Antibody Partnering Terms and Agreements, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cancer Monoclonal Antibody Partnering Terms and Agreements revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Cancer Monoclonal Antibody Partnering Terms and Agreements market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Cancer Monoclonal Antibody Partnering Terms and Agreements revenue, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Cancer Monoclonal Antibody Partnering Terms and Agreements Market Report

Report Metric	Details
Report Name	Cancer Monoclonal Antibody Partnering Terms and Agreements Market
Segment by Type	Asset Purchase Collaborative R&D Joint Venture Licensing Other
Segment by Application	Pharmaceutical Industry Biotechnology Medical Care Education and Research Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension, Ascentage Pharma, Aslan Pharma, Telix Pharmaceuticals, Basilea Pharmaceutica, Bavarian Nordic, Baxalta, Bayer, Cantargia, Apollomics, Chiome Bioscience, Clovis Oncology
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Cancer Monoclonal Antibody Partnering Terms and Agreements in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Monoclonal Antibody Partnering Terms and Agreements companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cancer Monoclonal Antibody Partnering Terms and Agreements revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report?

Ans: The main players in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market are 3SBio, 4D Pharma, Abbvie, Abzena, Adaptive Biotechnologies, Aeglea BioTherapeutics, Agenus Bio, Ascension, Ascentage Pharma, Aslan Pharma, Telix Pharmaceuticals, Basilea Pharmaceutica, Bavarian Nordic, Baxalta, Bayer, Cantargia, Apollomics, Chiome Bioscience, Clovis Oncology

What are the Application segmentation covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report?

Ans: The Applications covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report are Pharmaceutical Industry, Biotechnology, Medical Care, Education and Research, Other

What are the Type segmentation covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report?

Ans: The Types covered in the Cancer Monoclonal Antibody Partnering Terms and Agreements Market report are Asset Purchase, Collaborative R&D, Joint Venture, Licensing, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Asset Purchase

1.2.3 Collaborative R&D

1.2.4 Joint Venture

1.2.5 Licensing

1.2.6 Other

1.3 Market by Application

1.3.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Pharmaceutical Industry

1.3.3 Biotechnology

1.3.4 Medical Care

1.3.5 Education and Research

1.3.6 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Perspective (2019-2030)

2.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Trends by Region

2.2.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Region (2019-2024)

2.2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2025-2030)

2.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Dynamics

2.3.1 Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Trends

2.3.2 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers

2.3.3 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges

2.3.4 Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints

3 Competition Landscape by Key Players

3.1 Global Revenue Cancer Monoclonal Antibody Partnering Terms and Agreements by Players

3.1.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2019-2024)

3.1.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Players (2019-2024)

3.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements, Ranking by Revenue, 2022 VS 2023 VS 2024

3.4 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio

3.4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2023

3.5 Global Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements Head office and Area Served

3.6 Global Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements, Product and Application

3.7 Global Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Type

4.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Type (2019-2024)

4.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2025-2030)

5 Cancer Monoclonal Antibody Partnering Terms and Agreements Breakdown Data by Application

5.1 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Historic Market Size by Application (2019-2024)

5.2 Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

6.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type

6.2.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024)

6.2.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030)

6.2.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

6.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application

6.3.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024)

6.3.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030)

6.3.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

6.4 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country

6.4.1 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country: 2019 VS 2023 VS 2030

6.4.2 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024)

6.4.3 North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030)

6.4.4 U.S.

6.4.5 Canada

7 Europe

7.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

7.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type

7.2.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024)

7.2.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030)

7.2.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

7.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application

7.3.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024)

7.3.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030)

7.3.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

7.4 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country

7.4.1 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country: 2019 VS 2023 VS 2030

7.4.2 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024)

7.4.3 Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030)

7.4.3 Germany

7.4.4 France

7.4.5 U.K.

7.4.6 Italy

7.4.7 Russia

7.4.8 Nordic Countries

8 China

8.1 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

8.2 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type

8.2.1 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024)

8.2.2 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030)

8.2.3 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

8.3 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application

8.3.1 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024)

8.3.2 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030)

8.3.3 China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

9.2 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type

9.2.1 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024)

9.2.2 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030)

9.2.3 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

9.3 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application

9.3.1 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024)

9.3.2 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030)

9.3.3 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

9.4 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region

9.4.1 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region: 2019 VS 2023 VS 2030

9.4.2 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2019-2024)

9.4.3 Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2025-2030)

9.4.4 Japan

9.4.5 South Korea

9.4.6 China Taiwan

9.4.7 Southeast Asia

9.4.8 India

9.4.9 Australia

10 Middle East, Africa, and Latin America

10.1 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (2019-2030)

10.2 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type

10.2.1 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024)

10.2.2 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030)

10.2.3 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

10.3 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application

10.3.1 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024)

10.3.2 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030)

10.3.3 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

10.4 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country

10.4.1 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country: 2019 VS 2023 VS 2030

10.4.2 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024)

10.4.3 Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030)

10.4.4 Brazil

10.4.5 Mexico

10.4.6 Turkey

10.4.7 Saudi Arabia

10.4.8 Israel

10.4.9 GCC Countries

11 Key Players Profiles

11.1 3SBio

11.1.1 3SBio Company Details

11.1.2 3SBio Business Overview

11.1.3 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.1.4 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.1.5 3SBio Recent Developments

11.2 4D Pharma

11.2.1 4D Pharma Company Details

11.2.2 4D Pharma Business Overview

11.2.3 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.2.4 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.2.5 4D Pharma Recent Developments

11.3 Abbvie

11.3.1 Abbvie Company Details

11.3.2 Abbvie Business Overview

11.3.3 Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.3.4 Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.3.5 Abbvie Recent Developments

11.4 Abzena

11.4.1 Abzena Company Details

11.4.2 Abzena Business Overview

11.4.3 Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.4.4 Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.4.5 Abzena Recent Developments

11.5 Adaptive Biotechnologies

11.5.1 Adaptive Biotechnologies Company Details

11.5.2 Adaptive Biotechnologies Business Overview

11.5.3 Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.5.4 Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.5.5 Adaptive Biotechnologies Recent Developments

11.6 Aeglea BioTherapeutics

11.6.1 Aeglea BioTherapeutics Company Details

11.6.2 Aeglea BioTherapeutics Business Overview

11.6.3 Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.6.4 Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.6.5 Aeglea BioTherapeutics Recent Developments

11.7 Agenus Bio

11.7.1 Agenus Bio Company Details

11.7.2 Agenus Bio Business Overview

11.7.3 Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.7.4 Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.7.5 Agenus Bio Recent Developments

11.8 Ascension

11.8.1 Ascension Company Details

11.8.2 Ascension Business Overview

11.8.3 Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.8.4 Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.8.5 Ascension Recent Developments

11.9 Ascentage Pharma

11.9.1 Ascentage Pharma Company Details

11.9.2 Ascentage Pharma Business Overview

11.9.3 Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.9.4 Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.9.5 Ascentage Pharma Recent Developments

11.10 Aslan Pharma

11.10.1 Aslan Pharma Company Details

11.10.2 Aslan Pharma Business Overview

11.10.3 Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.10.4 Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.10.5 Aslan Pharma Recent Developments

11.11 Telix Pharmaceuticals

11.11.1 Telix Pharmaceuticals Company Details

11.11.2 Telix Pharmaceuticals Business Overview

11.11.3 Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.11.4 Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.11.5 Telix Pharmaceuticals Recent Developments

11.12 Basilea Pharmaceutica

11.12.1 Basilea Pharmaceutica Company Details

11.12.2 Basilea Pharmaceutica Business Overview

11.12.3 Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.12.4 Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.12.5 Basilea Pharmaceutica Recent Developments

11.13 Bavarian Nordic

11.13.1 Bavarian Nordic Company Details

11.13.2 Bavarian Nordic Business Overview

11.13.3 Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.13.4 Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.13.5 Bavarian Nordic Recent Developments

11.14 Baxalta

11.14.1 Baxalta Company Details

11.14.2 Baxalta Business Overview

11.14.3 Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.14.4 Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.14.5 Baxalta Recent Developments

11.15 Bayer

11.15.1 Bayer Company Details

11.15.2 Bayer Business Overview

11.15.3 Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.15.4 Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.15.5 Bayer Recent Developments

11.16 Cantargia

11.16.1 Cantargia Company Details

11.16.2 Cantargia Business Overview

11.16.3 Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.16.4 Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.16.5 Cantargia Recent Developments

11.17 Apollomics

11.17.1 Apollomics Company Details

11.17.2 Apollomics Business Overview

11.17.3 Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.17.4 Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.17.5 Apollomics Recent Developments

11.18 Chiome Bioscience

11.18.1 Chiome Bioscience Company Details

11.18.2 Chiome Bioscience Business Overview

11.18.3 Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.18.4 Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.18.5 Chiome Bioscience Recent Developments

11.19 Clovis Oncology

11.19.1 Clovis Oncology Company Details

11.19.2 Clovis Oncology Business Overview

11.19.3 Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Introduction

11.19.4 Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

11.19.5 Clovis Oncology Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Adaptive Biotechnologies

Aeglea BioTherapeutics

Telix Pharmaceuticals

Basilea Pharmaceutica

List of Tables

Table 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030

Table 2. Key Players of Asset Purchase

Table 3. Key Players of Collaborative R&D

Table 4. Key Players of Joint Venture

Table 5. Key Players of Licensing

Table 6. Key Players of Other

Table 7. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030

Table 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2019-2024) & (US$ Million)

Table 10. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2019-2024)

Table 11. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 12. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2025-2030)

Table 13. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Trends

Table 14. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Drivers

Table 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Challenges

Table 16. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Restraints

Table 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue by Players (2019-2024) & (US$ Million)

Table 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Players (2019-2024)

Table 19. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2023)

Table 20. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Industry Ranking 2022 VS 2023 VS 2024

Table 21. Global 5 Largest Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue (CR5 and HHI) & (2019-2024)

Table 22. Global Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements, Headquarters and Area Served

Table 23. Global Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements, Product and Application

Table 24. Global Key Players of Cancer Monoclonal Antibody Partnering Terms and Agreements, Product and Application

Table 25. Mergers & Acquisitions, Expansion Plans

Table 26. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024) & (US$ Million)

Table 27. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2019-2024)

Table 28. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 29. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Market Share by Type (2025-2030)

Table 30. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024) & (US$ Million)

Table 31. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Application (2019-2024)

Table 32. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 33. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue Share by Application (2025-2030)

Table 34. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024) & (US$ Million)

Table 35. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030) & (US$ Million)

Table 36. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024) & (US$ Million)

Table 37. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030) & (US$ Million)

Table 38. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 39. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024) & (US$ Million)

Table 40. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030) & (US$ Million)

Table 41. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024) & (US$ Million)

Table 42. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030) & (US$ Million)

Table 43. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024) & (US$ Million)

Table 44. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030) & (US$ Million)

Table 45. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024) & (US$ Million)

Table 47. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030) & (US$ Million)

Table 48. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024) & (US$ Million)

Table 49. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030) & (US$ Million)

Table 50. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024) & (US$ Million)

Table 51. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030) & (US$ Million)

Table 52. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024) & (US$ Million)

Table 53. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030) & (US$ Million)

Table 54. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024) & (US$ Million)

Table 55. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030) & (US$ Million)

Table 56. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030

Table 57. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2019-2024) & (US$ Million)

Table 58. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Region (2025-2030) & (US$ Million)

Table 59. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2019-2024) & (US$ Million)

Table 60. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Type (2025-2030) & (US$ Million)

Table 61. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2019-2024) & (US$ Million)

Table 62. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Application (2025-2030) & (US$ Million)

Table 63. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030

Table 64. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2019-2024) & (US$ Million)

Table 65. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size by Country (2025-2030) & (US$ Million)

Table 66. 3SBio Company Details

Table 67. 3SBio Business Overview

Table 68. 3SBio Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 69. 3SBio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 70. 3SBio Recent Developments

Table 71. 4D Pharma Company Details

Table 72. 4D Pharma Business Overview

Table 73. 4D Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 74. 4D Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 75. 4D Pharma Recent Developments

Table 76. Abbvie Company Details

Table 77. Abbvie Business Overview

Table 78. Abbvie Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 79. Abbvie Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 80. Abbvie Recent Developments

Table 81. Abzena Company Details

Table 82. Abzena Business Overview

Table 83. Abzena Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 84. Abzena Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 85. Abzena Recent Developments

Table 86. Adaptive Biotechnologies Company Details

Table 87. Adaptive Biotechnologies Business Overview

Table 88. Adaptive Biotechnologies Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 89. Adaptive Biotechnologies Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 90. Adaptive Biotechnologies Recent Developments

Table 91. Aeglea BioTherapeutics Company Details

Table 92. Aeglea BioTherapeutics Business Overview

Table 93. Aeglea BioTherapeutics Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 94. Aeglea BioTherapeutics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 95. Aeglea BioTherapeutics Recent Developments

Table 96. Agenus Bio Company Details

Table 97. Agenus Bio Business Overview

Table 98. Agenus Bio Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 99. Agenus Bio Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 100. Agenus Bio Recent Developments

Table 101. Ascension Company Details

Table 102. Ascension Business Overview

Table 103. Ascension Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 104. Ascension Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 105. Ascension Recent Developments

Table 106. Ascentage Pharma Company Details

Table 107. Ascentage Pharma Business Overview

Table 108. Ascentage Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 109. Ascentage Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 110. Ascentage Pharma Recent Developments

Table 111. Aslan Pharma Company Details

Table 112. Aslan Pharma Business Overview

Table 113. Aslan Pharma Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 114. Aslan Pharma Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 115. Aslan Pharma Recent Developments

Table 116. Telix Pharmaceuticals Company Details

Table 117. Telix Pharmaceuticals Business Overview

Table 118. Telix Pharmaceuticals Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 119. Telix Pharmaceuticals Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 120. Telix Pharmaceuticals Recent Developments

Table 121. Basilea Pharmaceutica Company Details

Table 122. Basilea Pharmaceutica Business Overview

Table 123. Basilea Pharmaceutica Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 124. Basilea Pharmaceutica Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 125. Basilea Pharmaceutica Recent Developments

Table 126. Bavarian Nordic Company Details

Table 127. Bavarian Nordic Business Overview

Table 128. Bavarian Nordic Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 129. Bavarian Nordic Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 130. Bavarian Nordic Recent Developments

Table 131. Baxalta Company Details

Table 132. Baxalta Business Overview

Table 133. Baxalta Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 134. Baxalta Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 135. Baxalta Recent Developments

Table 136. Bayer Company Details

Table 137. Bayer Business Overview

Table 138. Bayer Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 139. Bayer Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 140. Bayer Recent Developments

Table 141. Cantargia Company Details

Table 142. Cantargia Business Overview

Table 143. Cantargia Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 144. Cantargia Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 145. Cantargia Recent Developments

Table 146. Apollomics Company Details

Table 147. Apollomics Business Overview

Table 148. Apollomics Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 149. Apollomics Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 150. Apollomics Recent Developments

Table 151. Chiome Bioscience Company Details

Table 152. Chiome Bioscience Business Overview

Table 153. Chiome Bioscience Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 154. Chiome Bioscience Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 155. Chiome Bioscience Recent Developments

Table 156. Clovis Oncology Company Details

Table 157. Clovis Oncology Business Overview

Table 158. Clovis Oncology Cancer Monoclonal Antibody Partnering Terms and Agreements Product

Table 159. Clovis Oncology Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024) & (US$ Million)

Table 160. Clovis Oncology Recent Developments

Table 161. Research Programs/Design for This Report

Table 162. Key Data Information from Secondary Sources

Table 163. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 2. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type: 2023 VS 2030

Figure 3. Asset Purchase Features

Figure 4. Collaborative R&D Features

Figure 5. Joint Venture Features

Figure 6. Licensing Features

Figure 7. Other Features

Figure 8. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 9. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application: 2023 VS 2030

Figure 10. Pharmaceutical Industry Case Studies

Figure 11. Biotechnology Case Studies

Figure 12. Medical Care Case Studies

Figure 13. Education and Research Case Studies

Figure 14. Other Case Studies

Figure 15. Cancer Monoclonal Antibody Partnering Terms and Agreements Report Years Considered

Figure 16. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 17. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 18. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region: 2023 VS 2030

Figure 19. Global Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Players in 2023

Figure 20. Global Top Cancer Monoclonal Antibody Partnering Terms and Agreements Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Monoclonal Antibody Partnering Terms and Agreements as of 2023)

Figure 21. The Top 10 and 5 Players Market Share by Cancer Monoclonal Antibody Partnering Terms and Agreements Revenue in 2023

Figure 22. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

Figure 24. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

Figure 25. North America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2019-2030)

Figure 26. United States Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. Canada Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2019-2030) & (US$ Million)

Figure 29. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

Figure 30. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

Figure 31. Europe Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2019-2030)

Figure 32. Germany Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. France Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. U.K. Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Italy Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Russia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Nordic Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2019-2030) & (US$ Million)

Figure 39. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

Figure 40. China Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

Figure 41. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2019-2030) & (US$ Million)

Figure 42. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

Figure 43. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

Figure 44. Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Region (2019-2030)

Figure 45. Japan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. South Korea Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. China Taiwan Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Southeast Asia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 49. India Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 50. Australia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 51. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY (2019-2030) & (US$ Million)

Figure 52. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Type (2019-2030)

Figure 53. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Application (2019-2030)

Figure 54. Middle East, Africa, and Latin America Cancer Monoclonal Antibody Partnering Terms and Agreements Market Share by Country (2019-2030)

Figure 55. Brazil Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 56. Mexico Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 57. Turkey Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 58. Saudi Arabia Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 59. Israel Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 60. GCC Countries Cancer Monoclonal Antibody Partnering Terms and Agreements Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 61. 3SBio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 62. 4D Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 63. Abbvie Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 64. Abzena Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 65. Adaptive Biotechnologies Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 66. Aeglea BioTherapeutics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 67. Agenus Bio Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 68. Ascension Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 69. Ascentage Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 70. Aslan Pharma Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 71. Telix Pharmaceuticals Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 72. Basilea Pharmaceutica Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 73. Bavarian Nordic Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 74. Baxalta Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 75. Bayer Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 76. Cantargia Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 77. Apollomics Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 78. Chiome Bioscience Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 79. Clovis Oncology Revenue Growth Rate in Cancer Monoclonal Antibody Partnering Terms and Agreements Business (2019-2024)

Figure 80. Bottom-up and Top-down Approaches for This Report

Figure 81. Data Triangulation

Figure 82. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions